Lincoln Pharmaceuticals reports Q2 profit dip, targets Rs 1,000 crore revenue

Lincoln Pharmaceuticals Limited reported a consolidated net profit of Rs. 20.01 crore for Q2 FY26, a 24.06% year-over-year decrease from Rs. 26.35 crore in Q2 FY25. Total income for the quarter was Rs. 170.60 crore, a slight dip of 0.34% year-over-year.

For the half year ended September 30, 2025, consolidated net profit was Rs. 47.71 crore, down 4.64% from Rs. 50.03 crore in HI FY25, while total income increased by 3.36% to Rs. 339.93 crore. The board also approved a dividend of Rs. 1.80 per share (18%) for FY24-25.

The company is targeting a revenue of Rs. 1,000 crore within the next three years and aims for a 15-18% annual growth rate, driven by expansion into high-value therapeutic segments and new product introductions. Foreign Institutional Investors (FIIs) have increased their holding to 4.73% as of September 30, 2025.

The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were reviewed by the audit committee and approved by the board of directors on November 13, 2025. The full financial results are accessible on the company's website.